Loading...
Loading...
Size: 10mg
Secretagogue Peptide
In stock · Ships same day · Free shipping over $150
The CJC-1295/Ipamorelin combination pairs a growth hormone-releasing hormone (GHRH) analog with a selective growth hormone secretagogue peptide (GHSP) to activate two complementary pathways of GH release simultaneously. CJC-1295 (Mod GRF 1-29) binds to GHRH receptors on somatotroph cells in the anterior pituitary, amplifying the amplitude of GH pulses, while Ipamorelin activates the ghrelin receptor (GHS-R1a) to increase the frequency of GH release without elevating cortisol or prolactin. Published research demonstrates that this dual-pathway activation produces synergistic GH output that significantly exceeds the sum of either peptide administered alone, a phenomenon documented in comparative secretagogue studies. The Ipamorelin component is notable for its high selectivity among GH secretagogues, with peer-reviewed literature confirming it triggers GH release with minimal effect on ACTH, cortisol, or prolactin levels even at elevated doses. This combination has become the most widely referenced growth hormone secretagogue stack in research literature, studied for its effects on body composition, lean mass accretion, fat metabolism, sleep architecture, and recovery from tissue injury. The pre-combined formulation ensures consistent molar ratios between the two peptides, eliminating variability that can occur when researchers prepare separate solutions.
By simultaneously activating GHRH receptors (via CJC-1295) and ghrelin receptors (via Ipamorelin) on pituitary somatotroph cells, this combination produces a synergistic GH pulse that published research has documented as significantly greater than either peptide alone. The dual-pathway mechanism increases both the amplitude and frequency of GH secretion pulses, mimicking the body's natural multi-signal approach to growth hormone regulation.
The Ipamorelin component provides exceptionally selective GH release without the cortisol and prolactin elevation commonly observed with other GH secretagogues such as GHRP-6 or GHRP-2. Published research in the European Journal of Endocrinology confirmed that Ipamorelin does not significantly affect ACTH, cortisol, or prolactin even at supraphysiological doses, making this combination uniquely suited for research requiring isolated GH axis stimulation.
The pre-combined formulation delivers both peptides in a verified molar ratio within a single vial, eliminating the need to reconstitute, calculate, and draw from separate vials. This reduces preparation variability and potential contamination risks associated with handling multiple vials, which is particularly important for research protocols requiring consistent dosing across multiple administration time points.
Published research protocols reference subcutaneous administration 1-3 times daily. Store refrigerated at 2-8°C.
Every batch is independently analyzed by a third-party laboratory for purity and identity before release. A batch-specific Certificate of Analysis (COA) is available for each lot.
Purity
99.2%
Lab
Janoshik Analytical Laboratory
Batch
CJC129-2025-001
Test Date
2025-02-23
Orders placed before our daily cutoff ship the same business day. Free shipping on orders over $150, with tracking emailed as soon as your order leaves our facility.
Shipment protection covers your order against loss or damage in transit — if a protected order is lost or arrives damaged, our support team will arrange a replacement or resolution.
For in-vitro research and laboratory use only. This product is not a drug, supplement, food, or cosmetic, and has not been evaluated by the FDA.
Use is restricted to qualified researchers and laboratories operating within all applicable institutional, legal, and ethical guidelines. By purchasing, you confirm you are acquiring this product solely for lawful research purposes.
Store the CJC-1295/Ipamorelin combo lyophilized at -20°C for long-term storage. Once reconstituted with bacteriostatic water, store at 2-8°C (refrigerator) and use within 30 days. Both peptides in this combination have good reconstituted stability at refrigerator temperatures, but as with all peptide blends, minimize exposure to room temperature during handling to preserve the integrity of both active compounds.
Every batch of the CJC-1295/Ipamorelin combo is tested by Janoshik Analytical Laboratory using HPLC to verify the purity and ratio of both peptides in the blend, along with mass spectrometry to confirm the molecular identity of each component. Combo products require additional analytical validation to ensure both peptides are present at the correct molar ratio and that neither has degraded during the blending process. Our batches consistently achieve 99%+ purity for each component.
Reconstitute the CJC-1295/Ipamorelin combo with bacteriostatic water (BAC water) by slowly injecting the water along the vial wall. Allow both peptides to dissolve completely before use — this may take slightly longer than a single-peptide vial due to the combined lyophilized mass. Do not shake; gently swirl if needed. The reconstituted solution should appear clear and colorless.
This CJC-1295/Ipamorelin combination is sold for research purposes only and is not intended for human consumption. Both individual components have been the subject of published clinical studies — CJC-1295 in growth hormone release trials and Ipamorelin in selectivity and safety studies — but the combination product remains for investigational research use only. Consult with a qualified healthcare professional before designing any research protocol.
